- Startseite
- 4-6
- Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
4.6 (126) · € 17.50 · Auf Lager
Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis
IJMS, Free Full-Text
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival - ScienceDirect
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer - ScienceDirect
Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies - ScienceDirect
Full article: Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting - ScienceDirect
AGO Algorithms for the Treatment of Breast Cancer: Update 2021. - Abstract - Europe PMC
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status - Jiang - 2023 - International Journal of Cancer - Wiley Online Library
Frontiers Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
